We are analyzing https://link.springer.com/article/10.1007/s40265-016-0642-8.

Title:
Drug Treatment of Hypertension: Focus on Vascular Health | Drugs
Description:
Hypertension, the most common preventable risk factor for cardiovascular disease and death, is a growing health burden. Serious cardiovascular complications result from target organ damage including cerebrovascular disease, heart failure, ischaemic heart disease and renal failure. While many systems contribute to blood pressure (BP) elevation, the vascular system is particularly important because vascular dysfunction is a cause and consequence of hypertension. Hypertension is characterised by a vascular phenotype of endothelial dysfunction, arterial remodelling, vascular inflammation and increased stiffness. Antihypertensive drugs that influence vascular changes associated with high BP have greater efficacy for reducing cardiovascular risk than drugs that reduce BP, but have little or no effect on the adverse vascular phenotype. Angiotensin converting enzyme ACE inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) improve endothelial function and prevent vascular remodelling. Calcium channel blockers also improve endothelial function, although to a lesser extent than ACEIs and ARBs. Mineralocorticoid receptor blockers improve endothelial function and reduce arterial stiffness, and have recently become more established as antihypertensive drugs. Lifestyle factors are essential in preventing the adverse vascular changes associated with high BP and reducing associated cardiovascular risk. Clinicians and scientists should incorporate these factors into treatment decisions for patients with high BP, as well as in the development of new antihypertensive drugs that promote vascular health.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,734,772 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

pubmed, google, scholar, article, cas, hypertension, endothelial, vascular, central, blood, pressure, function, patients, circulation, heart, dysfunction, angiotensin, hypertens, effects, cardiovascular, nitric, essential, disease, oxide, artery, hypertensive, cells, endothelin, physiol, treatment, health, arterial, role, taddei, touyz, antihypertensive, aging, virdis, drugs, med, coronary, effect, receptor, ghiadoni, human, clin, enzyme, cell, circ, res,

Topics {✒️}

local intra-arterial ng-monomethyl-l-arginine transforming growth factor-β1-related transforming growth factor-beta1 month download article/chapter int/tobacco/publications/surveillance/fact_sheet_mortality_report arterial smooth-muscle cells endothelial nitric-oxide synthase pulse wave velocity restores age-related declines endothelium-derived relaxing factor nitric oxide-generating vasodilators endothelium-derived nitric oxide angiotensin-converting enzyme inhibitor angiotensin-converting enzyme inhibition angiotensin-converting enzyme inhibitors angiotensin ii receptor blockers improves endothelium-dependent vasodilation arterial smooth muscle low-density lipoprotein cholesterol end-stage renal disease tgf-beta1-dependent pathway high-normal blood pressure acetylcholine-induced cutaneous vasodilation central blood pressure central aortic pressure redox-sensitive vascular dysfunction target organ damage joint national committee schiffrin el tgf-beta-dependent high-dose oral vitamin angiotensin ii-mediated hypertension hypertension–reactive oxygen species long-term antihypertensive treatment nitric oxide availability nitric oxide deficiency angiotensin receptor blockers adverse long-term outcome arterial stiffening full article pdf sprint research group article drugs aims blood pressure lowering” von willebrand factor human endothelial cells flow-mediated dilation blake gj las heras de privacy choices/manage cookies reduce arterial stiffness

Questions {❓}

Benefits from angiotensin-converting enzyme inhibitor “beyond blood pressure lowering”: beyond blood pressure or beyond the brachial artery?
Cardiovascular benefits of aldosterone receptor antagonists: what about potassium?
Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both?
Hypertension guidelines: is it time to reappraise blood pressure thresholds and targets?
Reducing arterial stiffness and wave reflection—quest for the Holy Grail?
The endothelial cell nitric oxide synthase: is it really constitutively expressed?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Drug Treatment of Hypertension: Focus on Vascular Health
         description:Hypertension, the most common preventable risk factor for cardiovascular disease and death, is a growing health burden. Serious cardiovascular complications result from target organ damage including cerebrovascular disease, heart failure, ischaemic heart disease and renal failure. While many systems contribute to blood pressure (BP) elevation, the vascular system is particularly important because vascular dysfunction is a cause and consequence of hypertension. Hypertension is characterised by a vascular phenotype of endothelial dysfunction, arterial remodelling, vascular inflammation and increased stiffness. Antihypertensive drugs that influence vascular changes associated with high BP have greater efficacy for reducing cardiovascular risk than drugs that reduce BP, but have little or no effect on the adverse vascular phenotype. Angiotensin converting enzyme ACE inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) improve endothelial function and prevent vascular remodelling. Calcium channel blockers also improve endothelial function, although to a lesser extent than ACEIs and ARBs. Mineralocorticoid receptor blockers improve endothelial function and reduce arterial stiffness, and have recently become more established as antihypertensive drugs. Lifestyle factors are essential in preventing the adverse vascular changes associated with high BP and reducing associated cardiovascular risk. Clinicians and scientists should incorporate these factors into treatment decisions for patients with high BP, as well as in the development of new antihypertensive drugs that promote vascular health.
         datePublished:2016-09-26T00:00:00Z
         dateModified:2016-09-26T00:00:00Z
         pageStart:1529
         pageEnd:1550
         sameAs:https://doi.org/10.1007/s40265-016-0642-8
         keywords:
            Nitric Oxide
            Endothelial Dysfunction
            Endothelial Function
            Arterial Stiffness
            Pulse Wave Velocity
            Pharmacotherapy
            Pharmacology/Toxicology
            Internal Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-016-0642-8/MediaObjects/40265_2016_642_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-016-0642-8/MediaObjects/40265_2016_642_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-016-0642-8/MediaObjects/40265_2016_642_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-016-0642-8/MediaObjects/40265_2016_642_Fig4_HTML.gif
         isPartOf:
            name:Drugs
            issn:
               1179-1950
               0012-6667
            volumeNumber:76
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Alan C. Cameron
               affiliation:
                     name:University of Glasgow
                     address:
                        name:Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ninian N. Lang
               affiliation:
                     name:University of Glasgow
                     address:
                        name:Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rhian M. Touyz
               affiliation:
                     name:University of Glasgow
                     address:
                        name:Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Drug Treatment of Hypertension: Focus on Vascular Health
      description:Hypertension, the most common preventable risk factor for cardiovascular disease and death, is a growing health burden. Serious cardiovascular complications result from target organ damage including cerebrovascular disease, heart failure, ischaemic heart disease and renal failure. While many systems contribute to blood pressure (BP) elevation, the vascular system is particularly important because vascular dysfunction is a cause and consequence of hypertension. Hypertension is characterised by a vascular phenotype of endothelial dysfunction, arterial remodelling, vascular inflammation and increased stiffness. Antihypertensive drugs that influence vascular changes associated with high BP have greater efficacy for reducing cardiovascular risk than drugs that reduce BP, but have little or no effect on the adverse vascular phenotype. Angiotensin converting enzyme ACE inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) improve endothelial function and prevent vascular remodelling. Calcium channel blockers also improve endothelial function, although to a lesser extent than ACEIs and ARBs. Mineralocorticoid receptor blockers improve endothelial function and reduce arterial stiffness, and have recently become more established as antihypertensive drugs. Lifestyle factors are essential in preventing the adverse vascular changes associated with high BP and reducing associated cardiovascular risk. Clinicians and scientists should incorporate these factors into treatment decisions for patients with high BP, as well as in the development of new antihypertensive drugs that promote vascular health.
      datePublished:2016-09-26T00:00:00Z
      dateModified:2016-09-26T00:00:00Z
      pageStart:1529
      pageEnd:1550
      sameAs:https://doi.org/10.1007/s40265-016-0642-8
      keywords:
         Nitric Oxide
         Endothelial Dysfunction
         Endothelial Function
         Arterial Stiffness
         Pulse Wave Velocity
         Pharmacotherapy
         Pharmacology/Toxicology
         Internal Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-016-0642-8/MediaObjects/40265_2016_642_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-016-0642-8/MediaObjects/40265_2016_642_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-016-0642-8/MediaObjects/40265_2016_642_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-016-0642-8/MediaObjects/40265_2016_642_Fig4_HTML.gif
      isPartOf:
         name:Drugs
         issn:
            1179-1950
            0012-6667
         volumeNumber:76
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Alan C. Cameron
            affiliation:
                  name:University of Glasgow
                  address:
                     name:Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ninian N. Lang
            affiliation:
                  name:University of Glasgow
                  address:
                     name:Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rhian M. Touyz
            affiliation:
                  name:University of Glasgow
                  address:
                     name:Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Drugs
      issn:
         1179-1950
         0012-6667
      volumeNumber:76
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Glasgow
      address:
         name:Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
         type:PostalAddress
      name:University of Glasgow
      address:
         name:Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
         type:PostalAddress
      name:University of Glasgow
      address:
         name:Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Alan C. Cameron
      affiliation:
            name:University of Glasgow
            address:
               name:Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
               type:PostalAddress
            type:Organization
      name:Ninian N. Lang
      affiliation:
            name:University of Glasgow
            address:
               name:Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
               type:PostalAddress
            type:Organization
      name:Rhian M. Touyz
      affiliation:
            name:University of Glasgow
            address:
               name:Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
      name:Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
      name:Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(683)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

8.22s.

LINK . SPRINGER . COM {}